18.20
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals poised for growth with p... - pluang.com
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals synthesizes new menin/MLL interaction inhibitors - bioworld.com
Diaceutics (DXRX) Enhances Multi-Year Relay Collaboration with Syndax Pharmaceuticals to Advance Acute Leukaemia Precision Oncology Commercialisation - Kalkine Media
How Syndax Pharmaceuticals Inc. (SNDX) Affects Rotational Strategy Timing - Stock Traders Daily
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Bank of America Corp DE Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals stock holds recent gains as investor conferences and cancer drug outlook draw - ad-hoc-news.de
Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis: Unveiling a 112% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Syndax Pharmaceuticals stock gains on investor conference schedule and steady September trading - ad-hoc-news.de
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WINTON GROUP Ltd Has $1.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
How (SNDX) Movements Inform Risk Allocation Models - Stock Traders Daily
Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - webull.com
Two talks by Syndax executives will be webcast live from New York in September. - Stock Titan
Squarepoint Ops LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6%Here's Why - MarketBeat
Syndax Pharmaceuticals at Citigroup’s Biopharma Back to School Summit 2026: revuforj gains - Investing.com India
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Price Forecast. Should You Buy SNDX? - StockInvest.us
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
Syndax Pharmaceuticals Inc. (SNDX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Peer Comparison – Compare with Others - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Syndax Pharmaceuticals Inc. (SNDX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Syndax stock gains attention as investor conferences approach - ad-hoc-news.de
Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Alyeska Investment Group L.P. Acquires Shares of 308,507 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Announces Participation in September Investor Conferences - GlobeNewswire
Man Group plc Takes $4.67 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Bank of New York Mellon Corp Makes New $22.74 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Q2 2026 Earnings: Wider-than-Expected EPS Loss Triggers Share DeclineEarnings Manipulation Risk - vinanet.vn
Ieq Capital LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Has $22.98 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Parkman Healthcare Partners LLC Purchases New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Maintained by UBS -- Price Target Lowered to $33 - GuruFocus
UBS lowers Syndax Pharmaceuticals price target on revenue outlook - Investing.com
UBS lowers Syndax Pharmaceuticals price target on revenue outlook By Investing.com - Investing.com Canada
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating - Yahoo Finance
Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Eastern Progress
Syndax (SNDX) Quarterly Results: Profit Per Share Falls Below Its Benchmark in the Reported Period; Trading Move - careplusvn.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet - Eastern Progress
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Syndax Pharmaceuticals (SNDX) Edges Up 0.46% to $19.85 as Range-Bound Trading PersistsHigh Low Breadth - vinanet.vn
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Breakeven? - news.futunn.com
GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stifel Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
SNDX Stock Price, Quote & Chart - ChartMill
The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
SNDX Maintained by JP Morgan -- Price Target Lowered to $40.00 - GuruFocus
大文字化:
|
ボリューム (24 時間):